IJCRT.ORG ISSN : 2320-2882

INTERNATIONAL JOURNAL OF CREATIVE RESEARCH THOUGHTS (IJCRT)

An International Open Access, Peer-reviewed, Refereed Journal

Prescription Pattern Analysis Of Anti-Diabetic Drugs In Secondary Care Hospitals

[1]Narzia Begum, [2]Prof. Dr. Dharmendra Ahuja, [3]Sarila, [3]Anshul Saini

[1] Student, Faculty of Pharmaceutical Science, Jayoti Vidyapeeth Women's University, Jaipur, India.

[2] Dean cum Director, Faculty of Pharmaceutical Science, Jayoti Vidyapeeth Women's University, Jaipur, India.

[3] Assistant Professor, Faculty of Pharmaceutical Science, Jayoti Vidyapeeth Women's University, Jaipur, India.

Abstract

Diabetes mellitus is a long-term metabolic condition by elevated blood sugar levels due to problems with insulin production, insulin function, or a combination of both. Effective Diabetes management strategy requires careful selection and monitoring of pharmacological therapy. This review focuses on prescription pattern analysis of anti-diabetic drugs in secondary care hospitals, emphasizing the trends, efficacy, and compliance observed in real-world settings. Understanding these patterns can guide clinicians in optimizing treatment strategies and improving patient outcomes.

1.Introduction

Diabetes mellitus has emerged as a significant public health concern globally, with an alarming increase in prevalence over the last few decades. As per the International Diabetes Federation, the worldwide occurrence of diabetes is projected to hike to unprecedented levels in the coming decades, fueled by urbanization, sedentary lifestyles, and unhealthy dietary habits. The condition is linked with Preeclampsias like heart diseases, kidney disfunction , vision problems, and nerve damage, all of which lead to higher rates of illness and death.

Successful control of diabetes demands a multifaceted tactics, inertia lifestyle modification, clinical education, and pharmacological intervention. The choice of pharmacological therapy depends on variety

of factors, such as the type of diabetes, glycemic control goals, the presence of co-morbidities, and patient-specific characteristics. Secondary care hospitals serve as a critical link in the healthcare continuum, managing patients who need more specialized care than what primary care settings can provide but do not yet require tertiary care interventions.

Prescription pattern analysis plays a important role in understanding trends & practices in diabetes control. By evaluating the rationality, adherence to guidelines, and therapeutic outcomes, such analyses can identify gaps in care and opportunities for improvement. Moreover, they provide insights into the challenges faced by healthcare providers and patients, including issues related to drug availability, affordability, and adherence.

The review aims to help in comprehensive overview of prescription patterns of anti-diabetic drugs in secondary care hospitals. By analyzing current practices, this study seeks to highlight the strengths and limitations of existing approaches, ultimately guiding clinicians and policymakers in optimizing diabetes care and improving patient outcomes.

2.Types of Diabetes

Glucose metablosim disorder encompasses a range of glucose regulation disturbance (excess glucose in the bloodstream). This condition occurs when the body cannot produce enough insulin or can not able to systematically utilize the insulin it produces. Insulin is a hormone that facilitates the entry of glucose into cells for energy.

The leading types of diabetes are:

1. Type 1 Diabetes

Type 1 diabetes is an autoimmune condition in which the immune system targets and damages the insulin-producing beta cells in the pancreas. This form of diabetes usually develops in childhood or early adulthood, although it can be diagnosed at any age.

Key Characteristics:

- **Insulin Dependency**: Individuals with Type 1 diabetes need to administer insulin daily since their bodies can no longer produce it.
- **Symptoms**: The onset of Type 1 diabetes is typically sudden and intense. Common symptoms include extreme thirst, frequent urination, unexplained weight loss, blurred vision, and fatigue.
- **Cause**: The exact cause is unknown, but genetic factors and an autoimmune response are considered significant contributors.
- **Management**: People with Type 1 diabetes must monitor their blood sugar levels closely, administer insulin, and maintain a healthy diet and lifestyle.

Preeclampsias:

- If left unmanaged, Type 1 diabetes can lead to Preeclampsias like diabetic ketoacidosis (DKA), nerve damage, kidney disease, eye problems, and cardiovascular disease.

2. Type 2 Diabetes

Type 2 diabetes is the most common form of diabetes, accounting for about 90-95% of all diabetes cases. It generally develops in adults, but rising numbers of children and adolescents are being diagnosed due to increasing obesity rates.

Key Characteristics:

- **Insulin Resistance**: In Type 2 diabetes, the body becomes resistant to the effects of insulin, or the pancreas doesn't produce enough insulin. As a result, blood sugar levels rise.
- **Symptoms**: Similar to Type 1, though they may be less pronounced and develop gradually. Symptoms include fatigue, excessive thirst, frequent urination, and slow-healing sores.
- **Cause**: A combination of genetic and environmental factors, including obesity, lack of physical activity, and poor diet, contribute to its development.

Management:

- Lifestyle changes such as diet and exercise are crucial for managing Type 2 diabetes. Oral medications, including metformin and sulfonylureas, may also be used. In some cases, insulin therapy is required.
- Monitoring blood glucose levels regularly is necessary to prevent Preeclampsias.

Preeclampsias:

- Long-term high blood sugar can lead to serious Preeclampsias, such as heart disease, stroke, kidney damage, nerve damage, and poor circulation in the feet.

3. Diabetes of pregnancy

Diabetes of pregnancy is a state that arises about pregnancy when body not able produce enough insulin to meet the hikes needs. Although it typically resolves after childbirth, women who have had stomach diabetes are like likely to develop Type two diabetes later at life. Additionally, both the mother and the baby may experience Preeclampsias during pregnancy, such as high birth weight or premature delivery. Lifestyle changes, including a balanced diet & regular exercise, can help reduce the risk of increasing Type 2 diabetes after Diabetes of pregnancy.

Key Characteristics:

- **Onset**: It usually evolve during the 2nd or 3rd trimester of pregnancy.
- **Cause**: Hormonal transformation during pregnancy can lead to insulin refusal, causing blood sugar levels to rise.
- **Symptoms**: Often there are no noticeable symptoms, which is why testing is done as part of prenatal care.

Management:

- Diet, exercise, and blood sugar monitoring are typically used to manage Diabetes of pregnancy. If necessary, insulin injections may be prescribed.
- After birth, blood glucose levels usually return to normal, but the risk of Type 2 diabetes in the future is higher.

Preeclampsias:

If Diabetes of pregnancy is not effectively controlled, it may lead to Preeclampsias such as excessive birth weight. (which may necessitate a C-section), premature birth, or low blood sugar levels in the newborn after delivery.

4. Monogenic Diabetes

Monogenic diabetes is a rare form of diabetes. resulting from a mutation in a single gene. It is inherited and typically occurs in younger individuals.

Key Characteristics:

- **Genetic Mutations**: Unlike Type 1 and Type 2, which involve multiple genetic and environmental factors, monogenic diabetes results from a single gene mutation.
- **Two Main Forms**: The two primary types are neonatal diabetes (diagnosed within the first six months of life) and maturity-onset diabetes of the young (MODY) (usually diagnosed before the age of 25).

Management:

- Depending on the specific genetic mutation, monogenic diabetes may be treated with oral medication or insulin.

Preeclampsias:

- Like Type 1 and Type 2 diabetes, if poorly managed, it can lead to long-term Preeclampsias such as kidney damage and nerve issues.

5. LADA (Latent Autoimmune Diabetes in Adults)

LADA is frequently referred to as a blend of Type 1 and Type 2 diabetes, exhibiting features of both conditions.

Key Characteristics:

- **Slow Progression**: LADA develops more slowly than Type 1 and often occurs in adults over 30.
- **Autoimmune Component :**Similar to Type 1 diabetes, LADA (Latent Autoimmune Diabetes in Adults) also involves an immune system assault on the insulin-secreting cells of the pancreas, but the progression is more gradual and less noticeable.
- **Diagnosis**: Often misdiagnosed as Type 2 diabetes because of its age of onset and gradual progression.

Management:

- LADA may initially be managed with oral medications, but insulin therapy becomes necessary as the autoimmune process progresses and insulin production diminishes.

6. Other Types of Diabetes

There are also other rare forms of diabetes that may result from specific causes, such as diseases, medications, or infections.

- **Steroid-induced diabetes**: Caused by the use of corticosteroids.
- **Cystic fibrosis-related diabetes**: Occurs in individuals with cystic fibrosis due to damage to the pancreas.
- **Alström syndrome and Wolfram syndrome**: Rare genetic disorders associated with diabetes.

Risk Factors for Developing Diabetes

The risk factors vary by type of diabetes:

- **Type 1 diabetes**: Family history and genetic predisposition.
- **Type 2 diabetes**: Obesity, age, family history, physical inactivity, poor diet, and ethnicity (e.g., African American, Latino, and Native American).

- **Diabetes of pregnancy**: Obesity, age, family history, and being of certain ethnic backgrounds increase the risk.

3.Prevention and Management

While Type 1 diabetes is not preventable, Type 2 diabetes and Diabetes of pregnancy can frequently be controlled or avoided through modifications in daily habits, such as:

- **Diet**: Eating a balanced diet rich in fruits, vegetables, and whole grains.
- **Exercise**: Regular physical activity helps maintain a healthy weight and improves insulin sensitivity.
- **Monitoring**: Regular blood glucose monitoring is essential for all types of diabetes.

4. Objectives

The primary objectives of prescription pattern analysis in secondary care hospitals include:

1. Identifying the most commonly prescribed anti-diabetic medications across different patient demographics.
2. Analyzing trends in monotherapy versus combination therapy to understand their impact on glycemic control and patient adherence.
3. Assessing the rationality of prescriptions by comparing them against established national and international treatment guidelines.
4. Evaluating patient compliance and identifying factors influencing adherence to prescribed treatment regimens.
5. Investigating the role of co-morbid conditions such as hypertension, dyslipidemia, and obesity in shaping prescription patterns.
6. Highlighting the influence of hospital policies, drug availability, and economic factors on prescribing behaviors.
7. Identifying gaps in current practices and proposing actionable recommendations for improving diabetes management in secondary care settings.

5.Methodology

A systematic review of studies conducted on prescription patterns of anti-diabetic drugs in secondary care settings was undertaken. Data from electronic health records, prescriptions, and observational studies were analyzed. Key parameters included drug classes, combination therapy, adherence to treatment guidelines, and patient demographics.

Medication Patterns

1. **Classes of Anti-Diabetic Drugs**
    - **Biguanides:** Metformin remains the most prescribed first-line agent due to its efficacy, safety profile, and cost-effectiveness. Its role in improving insulin sensitivity and reducing cardiovascular risk makes it a cornerstone in diabetes management.
    - **Sulfonylureas:** These are commonly prescribed as add-on therapy, particularly in patients with inadequate glycemic control on metformin alone. However, concerns about hypoglycemia and weight gain limit their use.
    - **Dipeptidyl Peptidase-4 (DPP-4) Inhibitors:** These agents are increasingly favored for their glucose-lowering effects with a minimal risk of hypoglycemia.
    - **Sodium-Glucose Co-Transporter-2 (SGLT-2) Inhibitors:** Recent trends show a rise in SGLT-2 inhibitor prescriptions due to their benefits in cardiovascular and renal outcomes.
    - **Glucagon-Like Peptide-1 (GLP-1) Receptor Agonists:** These are particularly effective in weight reduction and cardiovascular risk mitigation, making them a preferred choice for certain populations.
    - **Thiazolidinediones (TZDs):** Though less commonly used due to concerns over side effects like fluid retention and weight gain, TZDs are effective in improving insulin sensitivity.
    - **Insulin Therapy:** Insulin is frequently prescribed for patients with type 1 diabetes and poorly controlled type 2 diabetes, especially in the presence of significant hyperglycemia or Preeclampsias.
2. **Combination Therapy**
    - Combination therapy is prevalent in secondary care settings to achieve optimal glycemic control. Fixed-dose combinations, such as metformin with sulfonylureas or DPP-4 inhibitors, improve patient compliance by simplifying the regimen.
3. **Rationality of Prescriptions**
    - Studies indicate variability in adherence to international and national treatment guidelines. Some prescriptions deviate due to patient-specific factors like co-morbidities, financial constraints, and availability of drugs.
4. **Impact of Co-Morbid Conditions**
    - Hypertension, dyslipidemia, and obesity significantly influence the choice of anti-diabetic medications. Drugs like SGLT-2 inhibitors and GLP-1 receptor agonists are preferred in patients with cardiovascular risk factors.
5. **Challenges in Prescription Practices**
    - Inadequate patient education, financial barriers, and limited access to advanced therapies are prominent challenges in secondary care settings. Additionally, polypharmacy poses a risk of drug interactions and adverse effects.

6.Limitations of the Study

1. **Limited Generalizability:** The findings may not be representative of all secondary care hospitals, as prescription practices can vary significantly based on regional, institutional, and economic factors.
2. **Data Availability:** The study relies on available prescription records, which may not capture all relevant patient information, such as adherence, outcomes, or reasons for therapy changes.
3. **Patient-Specific Factors:** Variability in patient demographics, co-morbidities, and socio-economic status can influence prescription patterns, complicating the analysis.
4. **Guideline Variability:** Differences in adherence to national versus international treatment guidelines can impact the interpretation of rationality in prescribing.
5. **Focus on Pharmacological Aspects:** Non-pharmacological interventions, such as lifestyle modifications and patient education, are not explored in this review.
6. **Time Frame:** Prescription patterns can evolve rapidly, and findings may not reflect current practices due to the time lag in data collection and analysis.

Acknowledgment

I express my heartfelt gratitude to Jayoti Vidyapeeth Women's University for providing the resources and support essential for completing this review. I sincerely thank my mentor, Dr. Dharmendra Ahuja, and my faculty Assistant professor Sarila and Assistant professor Anshul Saini for his invaluable guidance and constructive feedback throughout this endeavour . Lastly I wants to thank My father Mr. Nazir Ahmed, My Mother Mrs. Angura Begum and My elder sister Ms. Shahsnaz Begum has always given me support, motivation and inspiration in every situation of my life.

References

1. Nathan, D. M., et al. (2009). Medical management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy. Diabetes Care, 32(1), 193-203.
2. Abdul-Ghani, M. A., et al. (2006). Role of beta-cell dysfunction in the pathogenesis of type 2 diabetes. Endocrine Reviews, 27(5), 620-631.
3. UK Prospective Diabetes Study (UKPDS) Group. (1998). Effect of intensive blood-glucose control with metformin on Preeclampsias in overweight patients with type 2 diabetes. The Lancet, 352(9131), 854-865.
4. Garber, A. J., et al. (2018). Consensus statement by the American Association of Clinical Endocrinologists and American College of Endocrinology on the comprehensive type 2 diabetes management algorithm—2018 Executive Summary. Endocrine Practice, 24(1), 91-120.
5. DeFronzo, R. A., et al. (2015). Type 2 diabetes mellitus. Nature Reviews Disease Primers, 1(1), 1-22.

6. Holman, R. R., et al. (2008). 10-year follow-up of intensive glucose control in type 2 diabetes. New England Journal of Medicine, 359(15), 1577-1589.
7. Bailey, C. J., & Day, C. (2004). Metformin: its botanical background and its role in diabetes management. Diabetes Care, 27(7), 1790-1791.
8. Zinman, B., et al. (2015). Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. New England Journal of Medicine, 373(22), 2117-2128.
9. Maruthur, N. M., et al. (2016). Diabetes medications as monotherapy or metformin-based combination therapy for type 2 diabetes: a systematic review and meta-analysis. Annals of Internal Medicine, 164(11), 740-751.
10. Brown, J. B., et al. (2004). The impact of diabetes mellitus on healthcare resource utilization and costs. Diabetes Care, 27(3), 608-615.
11. Riddle, M. C., et al. (2018). GLP-1 receptor agonists versus insulin in the treatment algorithm for type 2 diabetes. Endocrine Reviews, 39(6), 742-772.
12. Inzucchi, S. E., et al. (2012). Management of hyperglycemia in type 2 diabetes: a patient-centered approach. Diabetes Care, 35(6), 1364-1379.
13. Scheen, A. J. (2015). SGLT2 inhibitors: benefit/risk balance. Current Diabetes Reports, 15(8), 1-10.
14. Cefalu, W. T., et al. (2016). Advances in the pharmacologic management of type 2 diabetes: consensus report of the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care, 39(2), 266-269.